Validity of Natural Products Patents Called into Question
- Gregory Glass
- Asia IP
A recent article on United States Supreme Court decision in Association for Molecular Pathology v. Myriad Genetics quoted Sterne Kessler Director Robert W. Esmond, Ph.D. The article explains the Court's decision and how it will impact patents in the pharmaceuticals field.
"This decision rendered invalid patent claims owned by Myriad Genetics as well as thousands of patent claims of others to such molecules," Dr. Esmond said. "There are going to be many more lawsuits because of the uncertainty of what is patentable."
Subscribers can read the full article here.